Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis
A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Adolescents and Adults With Scalp and Body Psoriasis
Sponsor: Arcutis Biotherapeutics, Inc.
A PHASE2 clinical study on Plaque Psoriasis, this trial is completed. The trial is conducted by Arcutis Biotherapeutics, Inc. and has accumulated 16 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Oct 2022 — Nov 2022 [monthly]
Completed PHASE2
▶ Show 11 earlier versions
-
Apr 2022 — Oct 2022 [monthly]
Completed PHASE2
-
Sep 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE2
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE2
-
Mar 2020 — Jun 2020 [monthly]
Recruiting PHASE2
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE2
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Arcutis Biotherapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .